gp100 Melanoma Antigen
-
Subject Areas on Research
- Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.
- Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
- Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
- Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
- Functional heterogeneity of vaccine-induced CD8(+) T cells.
- Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
- Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity.
- Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression.
- Kinetics of TCR use in response to repeated epitope-specific immunization.
- Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases.
- Melanoma, a tumor based on a mutant stem cell?
- Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
- Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
- Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
- Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.